Similar to variants arising in BTK on BTKi therapy, variants in BCL2 that affect drug binding are the canonical direct resistance mechanism observed in patients with CLL treated with continuous venetoclax (Table 2 and Fig. 2). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.